Inflammation Blood Markers and Metabolic Problems in People With Overweight or Obesity
Studies whether two blood inflammation measures predict metabolic problems in adults with overweight or obesity.
Plain-language title generated from the registry record
Registry title: Prognostic Value of SII and SIRI in Obesity-Related Metabolic Complications
Key facts
- Where
- Varaždin, CroatiaSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults who are overweight or obese. It studies two blood inflammation measures (SII and SIRI) and follows treatment results over 3 years.
- Age
- 18 years or older
- Sex
- All sexes can join.
- Disease stage
- Overweight (BMI 25.0-29.9 kg/m²) or obesity (BMI ≥ 30 kg/m²).
- Earlier treatment
- People using immunosuppressive therapy cannot join. Recent major surgery (within the last 3 months) also rules people out.
Main reasons for not taking part
- Pregnancy or breastfeeding
- Use of immunosuppressive therapy
- Active infection or acute illness affecting immune tests
- Inflammatory disease, malignancy, or known blood disorders affecting white blood cell or platelet counts
- Major surgery within the last 3 months
Read by machine on 13 November 2026.
Where in Croatia
- General Hospital VarazdinVaraždin, CroatiaContact: Jelena Vresk Špiranec, MD, specialist in endocrinologTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- University of Rijeka
- Trial code
- NCT07431593
- Record updated
- 7 May 2026
- Original description
This observational study aims to evaluate the diagnostic and prognostic value of the systemic immune-inflammatory index (SII) and the systemic inflammation response index (SIRI) in individuals with overweight or obesity. The study will assess their association with obesity status, metabolic complications, lifestyle patterns, dietary indices, and established inflammatory biomarkers. Participants will undergo anthropometric assessment, laboratory testing, dietary evaluation, and follow-up for response to different obesity treatment modalities over 3 years. The study intends to determine whether SII and SIRI can serve as clinically useful predictors of metabolic risk and treatment outcomes of obesity.Read full original descriptionShow less
Clinical Significance and Prognostic Value of Systemic Immune Inflammation Index and Systemic Inflammation Response Index in Obesity and Associated Metabolic Complications
This observational study aims to evaluate the diagnostic and prognostic value of the systemic immune-inflammatory index (SII) and the systemic inflammation response index (SIRI) in individuals with overweight or obesity. The study will assess their association with obesity status, metabolic complications, lifestyle patterns, dietary indices, and established inflammatory biomarkers. Participants will undergo anthropometric assessment, laboratory testing, dietary evaluation, and follow-up for response to different obesity treatment modalities over 3 years. The study intends to determine whether SII and SIRI can serve as clinically useful predictors of metabolic risk and treatment outcomes of obesity.
Inclusion: Age ≥ 18 years; BMI 25.0-29.9 kg/m² (overweight) or BMI ≥ 30 kg/m² (obesity); Ability to attend scheduled clinical visits; Willingness to provide informed consent.
Exclusion: Use of immunosuppressive therapy; Recent major surgery (within the last 3 months); Active infection; Inflammatory disease; Malignancy; Acute illness affecting immune parameters; Conditions interfering with study participation (as assessed by the investigator); Chronic inflammatory diseases requiring systemic therapy; Any condition that could confound the relationship between SII/SIRI and obesity-driven inflammation, such as immune disorders; Known hematologic disorders affecting leukocyte or platelet counts; Pregnancy or breastfeeding.